The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to compounders ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

Picture: Lezli+Rose/PA In what feels like the biggest health craze in years, weight loss jabs like semaglutide (Ozempic and Wegovy) or tirzepatide (Mounjaro) have exploded in popularity.

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

New research shows that semaglutide, the compound in the weight-loss drug ... Eli Lilly, which makes the competitor drugs Mounjaro and Zepbound, has also studied whether the compound in those ...

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...

Novo Nordisk has slashed its full-year revenue and profit forecasts for the first time since launching its blockbuster weight ...

A 2024 study suggests you may get better weight loss results with tirzepatide, the active ingredient in Zepbound and Mounjaro, than with semaglutide, the active ingredient in Ozempic and Wegovy.